Aim. To assess dynamics of glycated hemoglobin levels and insulin doses per kg bw in children and adolescents with poorly controlled type 1 diabetes mellitus using insulin pumps. Materials and methods. Retrospective analysis of HbA1c levels and insulin doses per kg bw in children aged 2-17 years with DM1 (mean duration 5.3?3.1) before and 18 months after onset of insulin pump therapy (Medtronic Minimed 712 and 722) with a short-acting insulin analog Novopramid (Novo Nordisk) or Humalog (Ely Lilly) given to 55 (52,4%) and 50 (47,6%) of the patients respectively. НbА1с level and mean daily insulin dose per kg bw were determined when a patient visited the doctors office every 3 months. Results. Insulin pump therapy in patients with initially poorly controlled DM1 resulted in a decrease of HbA1c from 9.8?0.8 to 7,8?0,5% within 18 months after its beginning (p

Objective of the Review: To discuss possible therapies for patients with type 2 diabetes mellitus (DM2) using up-to-date initiation and therapy intensification algorithms with antihyperglycemic drugs. Key Points. DM is still a burning issue all over the world. The recommendations for therapy initiation and intensification for DM2 patients are reviewed annually. This article describes various antihyperglycemic drug regimens. Conclusion. Currently, the guideline is to use sodium-glucose linked transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists at early stages of DM2 therapy, irrespective of glycated haemoglobin levels, if the patient has an atherosclerotic cardiovascular disease (ASCVD), cardiac failure, chronic renal diseases or factors of ASCVD risk. Keywords: type 2 diabetes mellitus, non-insulin antihyperglycemic therapy, antihyperglycemic drug regimen.